发布求助
文献互助 智能选刊 最新文献

Kidney cancer journal : official journal of the Kidney Cancer Association最新文献

筛选
英文 中文
Robotic-assisted cytoreductive partial nephrectomy for metastatic sarcomatoid renal cell carcinoma following dramatic response to combination immunotherapy in a young female. 机器人辅助的细胞减少性部分肾切除术治疗转移性肉瘤样肾细胞癌，在联合免疫治疗后显着反应。
Kidney cancer journal : official journal of the Kidney Cancer Association Pub Date : 2023-06-01
Yasin Bhanji, Ezra Baraban, Brian Antonucci, Yasser Ged, Nirmish Singla
{"title":"Robotic-assisted cytoreductive partial nephrectomy for metastatic sarcomatoid renal cell carcinoma following dramatic response to combination immunotherapy in a young female.","authors":"Yasin Bhanji, Ezra Baraban, Brian Antonucci, Yasser Ged, Nirmish Singla","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Novel immune checkpoint inhibitors (ICI) have yielded remarkable response rates in metastatic renal cell carcinoma (RCC), including sarcomatoid RCC (sRCC). Here, we show the feasibility and efficacy of robotic-assisted cytoreductive partial nephrectomy (cPN) following a remarkable response to combination ICI for metastatic sRCC in a young female. A female in her late 40s presented with poor-risk, metastatic sRCC emanating from a 6.5 cm left renal mass including pulmonary involvement, retroperitoneal lymphadenopathy, and a scalp metastasis. She received 4 cycles of combination ipilimumab and nivolumab followed by maintenance nivolumab with a remarkable and durable response. Given the apparent downstaging of her primary tumor, a robotic cPN was pursued for residual ypT1aNoRo sRCC and found to be both feasible and safe with exceptional perioperative outcomes. She has since done well clinically and oncologically. Our unique case of metastatic sRCC in a young female highlights several aspects pertinent to the contemporary management of metastatic RCC including the role for cytoreductive nephrectomy in selected patients, the safety and feasibility of a nephron-sparing and minimally-invasive approach to cytoreduction after downstaging with ICI, and remarkable sensitivity of sRCC-a classically aggressive entity-to ICI.</p>","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"21 2","pages":"15-18"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138048966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal Duration of Therapy in Metastatic RCC: Exploring Treatment-Free Survival with Checkpoint Inhibitors 转移性RCC的最佳治疗时间:探索检查点抑制剂的无治疗生存期
Kidney cancer journal : official journal of the Kidney Cancer Association Pub Date : 2022-09-29 DOI: 10.52733/kcj20n3-a1
Grayce Selig, C. Hoimes, Joe Bible, D. George, M. Harrison
{"title":"Optimal Duration of Therapy in Metastatic RCC: Exploring Treatment-Free Survival with Checkpoint Inhibitors","authors":"Grayce Selig, C. Hoimes, Joe Bible, D. George, M. Harrison","doi":"10.52733/kcj20n3-a1","DOIUrl":"https://doi.org/10.52733/kcj20n3-a1","url":null,"abstract":"The optimal duration of treatment for patients with metastatic renal cell carcinoma (mRCC) on dual immune checkpoint inhibitor (ICI) therapy remains unknown. However, there is evolving evidence that a portion of patients who achieve a complete or partial response will have a durable response, even after therapy discontinuation, leading to prolonged treatment-free survival (TFS). TFS with dual ICI is a phenomenon not seen with targeted agents and has the potential to improve patient reported outcomes and quality of life, without altering overall survival (OS). Despite this understanding, treatment of mRCC remains lifelong, as there has yet to be a prospective, randomized control trial to evaluate this key question. In this review, we analyze available studies in patients with mRCC on dual ICI therapy and propose considerations for early treatment discontinuation. Additionally, we discuss vital questions and the next steps to help physicians and patients navigate these challenging treatment decisions.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85158117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma 替沃扎尼加纳武单抗联合治疗肾细胞癌的最新进展
Kidney cancer journal : official journal of the Kidney Cancer Association Pub Date : 2022-06-02 DOI: 10.52733/kcj20n2-rt
Robert Motzer, T. Choueiri, L. Albiges, R. Figlin
{"title":"Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma","authors":"Robert Motzer, T. Choueiri, L. Albiges, R. Figlin","doi":"10.52733/kcj20n2-rt","DOIUrl":"https://doi.org/10.52733/kcj20n2-rt","url":null,"abstract":"The treatment landscape of advanced renal cell carcinoma (aRCC) has witnessed significant benefits from the introduction of VEGF TKI/ICI (vascular endothelial growth factor receptor tyrosine kinase inhibitor/immune checkpoint inhibitor) combination in the first-line treatment. Such outcome benefits could extend to the relapsed/refractory setting with an effective, well-tolerated novel combination. Since the U.S. FDA approval of tivozanib monotherapy for the treatment of adult patients with relapsed or refractory advanced RCC following two or more prior systemic therapies,1 there is growing interest in exploring its full potential in combination with anti-PD-1 like ICI agents. In this roundtable discussion, internationally renowned cancer experts brainstorm the potential immunomodulatory capabilities of tivozanib plus nivolumab combination as first-liane and beyond settings in patients with metastatic RCC. The expert panel also explore potential data from previous and ongoing clinical trials and shared their perspectives about a tolerable safety profile and promising antitumor efficacy","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"104 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72968575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kidney Cancer Research Highlights from ASCO 2022 Annual Meeting. ASCO 2022年年会肾癌研究亮点
Kidney cancer journal : official journal of the Kidney Cancer Association Pub Date : 2022-06-01
Yasser Ged, Nirmish Singla
{"title":"Kidney Cancer Research Highlights from ASCO 2022 Annual Meeting.","authors":"Yasser Ged,&nbsp;Nirmish Singla","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The 2022 American Society of Clinical Oncology (ASCO) annual meeting was held June 3-7, 2022, in Chicago, Illinois. This hybrid meeting gathered international cancer experts across multidisciplinary specialties and was held both virtually and in-person. Here, we highlight key kidney cancer research updates presented at the meeting. Slides from the meeting's presentations are available on the ASCO meeting library website.</p>","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"20 2","pages":"61-64"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9725101/pdf/nihms-1822583.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10321676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GU22 ASCO - IMPORTANT ABSTRACTS Gu22 asco -重要摘要
Kidney cancer journal : official journal of the Kidney Cancer Association Pub Date : 2022-03-16 DOI: 10.52733/kcj20n1-gu22abs
Robert Figlin
{"title":"GU22 ASCO - IMPORTANT ABSTRACTS","authors":"Robert Figlin","doi":"10.52733/kcj20n1-gu22abs","DOIUrl":"https://doi.org/10.52733/kcj20n1-gu22abs","url":null,"abstract":"GU22 ASCO - Important Abstracts presented in the field of Kidney Cancer at ASCO Genitourinary Cancers Symposium.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75110168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
20th Anniversary Issue of The Kidney Cancer Journal: Reflecting the Past, Celebrating the Present and Shaping the Future 《肾癌杂志》20周年纪念:回顾过去，庆祝现在，塑造未来
Kidney cancer journal : official journal of the Kidney Cancer Association Pub Date : 2022-03-16 DOI: 10.52733/kcj20n1-e
Robert Figlin
{"title":"20th Anniversary Issue of The Kidney Cancer Journal: Reflecting the Past, Celebrating the Present and Shaping the Future","authors":"Robert Figlin","doi":"10.52733/kcj20n1-e","DOIUrl":"https://doi.org/10.52733/kcj20n1-e","url":null,"abstract":"Dear Colleagues, It is with a great deal of pride that we celebrate the 20th Anniversary of The Kidney Cancer Journal and its continuing success as a renowned publication in the field of kidney cancers. The Kidney Cancer Journal published its first issue in 2003, and during the last two decades, it has grown rapidly in content, audience reach, and status. The journal's 20th anniversary, therefore, deserves a review of the journey that we've been through, as well as a look into its future. It seems appropriate to use this editorial to reflect upon these achievements – including the contribution that the Kidney Cancer Journal has made to the evolution of research within the discipline and awareness.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80532657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A 20-Year Retrospective of Kidney Cancer Journal: 2003-2022 肾癌20年回顾性研究杂志:2003-2022
Kidney cancer journal : official journal of the Kidney Cancer Association Pub Date : 2022-03-16 DOI: 10.52733/kcj20n1-20yr
S. Pazhanisamy
{"title":"A 20-Year Retrospective of Kidney Cancer Journal: 2003-2022","authors":"S. Pazhanisamy","doi":"10.52733/kcj20n1-20yr","DOIUrl":"https://doi.org/10.52733/kcj20n1-20yr","url":null,"abstract":"These 20 years of the Kidney Cancer Journal’s journey encapsulate the most dramatic advances ever achieved in the management of RCC. This Q&A with Editor-in-Chief Robert A. Figlin, MD, reflects on the last two decades of the journey, and significant milestones in the evolution of strategies and optimized outcomes.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"629 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79011171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ASCO GU22 – Kidney Cancer Highlights ASCO GU22 -肾癌亮点
Kidney cancer journal : official journal of the Kidney Cancer Association Pub Date : 2022-03-16 DOI: 10.52733/kcj20n1-gu2
J. Graham
{"title":"ASCO GU22 – Kidney Cancer Highlights","authors":"J. Graham","doi":"10.52733/kcj20n1-gu2","DOIUrl":"https://doi.org/10.52733/kcj20n1-gu2","url":null,"abstract":"The 2022 ASCO Genitourinary Cancers Symposium took place in San Francisco between February 17-19th. As always, the scientific program contained several exciting abstracts with a focus on prostate cancer, bladder cancer, and kidney cancer. Here we will highlight key abstracts related to kidney cancer/renal cell carcinoma presented at this year’s symposium.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"83 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79795979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Moving Beyond BMI – Developments in Body Composition and Muscle Measurement in Renal Cell Carcinoma 超越BMI -肾细胞癌中身体成分和肌肉测量的发展
Kidney cancer journal : official journal of the Kidney Cancer Association Pub Date : 2022-03-16 DOI: 10.52733/kcj20n1-r1
H. Dzimitrowicz, J. Infield, Fides Regina Schwartz, Rajan Gupta, Michael Harrison
{"title":"Moving Beyond BMI – Developments in Body Composition and Muscle Measurement in Renal Cell Carcinoma","authors":"H. Dzimitrowicz, J. Infield, Fides Regina Schwartz, Rajan Gupta, Michael Harrison","doi":"10.52733/kcj20n1-r1","DOIUrl":"https://doi.org/10.52733/kcj20n1-r1","url":null,"abstract":"Body composition, namely the distribution and quantification of muscle and adipose tissue, are of increasing interest as potential prognostic indicators in patients with renal cell carcinoma (RCC). Herein, we review the available literature examining body composition in relation to outcomes for patients with RCC, methodology used to quantify muscle and adipose tissue using cross-sectional imaging, and future directions for translation of these findings into clinical care.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77708790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances in BEMPEG (NKTR-214) plus NIVOLUMAB Combination Strategies in Advanced Renal Cell Carcinoma BEMPEG (NKTR-214)联合NIVOLUMAB治疗晚期肾细胞癌的最新进展
Kidney cancer journal : official journal of the Kidney Cancer Association Pub Date : 2022-03-16 DOI: 10.52733/kcj20n1-rt
N. Tannir, A. Siefker-Radtke, R. Figlin
{"title":"Recent Advances in BEMPEG (NKTR-214) plus NIVOLUMAB Combination Strategies in Advanced Renal Cell Carcinoma","authors":"N. Tannir, A. Siefker-Radtke, R. Figlin","doi":"10.52733/kcj20n1-rt","DOIUrl":"https://doi.org/10.52733/kcj20n1-rt","url":null,"abstract":"In this roundtable discussion, renowned cancer experts analyze the potential immunomodulatory capabilities of bempegaldesleukin (BEMPEG; NKTR- 214) in combination with an immune checkpoint inhibitor (CPI; anti-PD-1) in the therapeutic landscape of advanced renal cell carcinoma (aRCC) and other genitourinary cancers. The expert panel also shared their perspectives regarding the latest data from ongoing clinical trials which continue to show an encouraging efficacy and safety, risk/benefit of BEMPEG plus CPI combination.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78630561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信